Leerink Partnrs Brokers Lift Earnings Estimates for Exelixis

Exelixis, Inc. (NASDAQ:EXEL) – Equities researchers at Leerink Partnrs increased their FY2026 earnings per share (EPS) estimates for Exelixis in a research report issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now anticipates that the biotechnology company will post earnings per share of $2.56 for the year, up from their prior forecast of $2.54. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share.

Other equities research analysts have also recently issued research reports about the company. StockNews.com upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 19th. UBS Group increased their price objective on Exelixis from $30.00 to $34.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Citigroup boosted their target price on shares of Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Guggenheim reaffirmed a “buy” rating and set a $42.00 price target on shares of Exelixis in a research note on Wednesday, February 12th. Finally, Stifel Nicolaus lifted their price target on shares of Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $37.59.

Exelixis Price Performance

EXEL stock opened at $36.39 on Monday. Exelixis has a 12 month low of $20.14 and a 12 month high of $40.02. The firm has a market capitalization of $10.18 billion, a PE ratio of 20.56, a P/E/G ratio of 1.13 and a beta of 0.57. The company’s 50 day simple moving average is $35.72 and its 200-day simple moving average is $33.46.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%.

Institutional Investors Weigh In On Exelixis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. grew its stake in shares of Exelixis by 308.1% during the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock valued at $132,376,000 after acquiring an additional 3,001,204 shares in the last quarter. Norges Bank purchased a new position in Exelixis in the fourth quarter valued at about $94,867,000. Caisse DE Depot ET Placement DU Quebec grew its stake in Exelixis by 330.4% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company’s stock valued at $82,730,000 after purchasing an additional 1,907,167 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Exelixis by 104.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company’s stock worth $105,208,000 after purchasing an additional 1,613,482 shares during the last quarter. Finally, Voloridge Investment Management LLC purchased a new stake in Exelixis during the 4th quarter worth approximately $30,321,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Activity at Exelixis

In other news, Director Jack L. Wyszomierski sold 8,768 shares of Exelixis stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $37.80, for a total transaction of $331,430.40. Following the sale, the director now owns 356,605 shares in the company, valued at $13,479,669. This trade represents a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Patrick J. Haley sold 10,000 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total transaction of $388,000.00. Following the transaction, the executive vice president now directly owns 341,028 shares in the company, valued at approximately $13,231,886.40. The trade was a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.